Paradigm Biopharmaceuticals Ltd (PAR) - Total Assets
Based on the latest financial reports, Paradigm Biopharmaceuticals Ltd (PAR) holds total assets worth AU$24.57 Million AUD (≈ $17.39 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See what is Paradigm Biopharmaceuticals Ltd's book value for net asset value and shareholders' equity analysis.
Paradigm Biopharmaceuticals Ltd - Total Assets Trend (2014–2025)
This chart illustrates how Paradigm Biopharmaceuticals Ltd's total assets have evolved over time, based on quarterly financial data.
Paradigm Biopharmaceuticals Ltd - Asset Composition Analysis
Current Asset Composition (June 2025)
Paradigm Biopharmaceuticals Ltd's total assets of AU$24.57 Million consist of 98.2% current assets and 1.8% non-current assets.
| Asset Category | Amount (AUD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$0.00 | 68.5% |
| Accounts Receivable | AU$6.37 Million | 25.9% |
| Inventory | AU$0.00 | 0.0% |
| Property, Plant & Equipment | AU$29.83K | 0.1% |
| Intangible Assets | AU$414.74K | 1.7% |
| Goodwill | AU$0.00 | 0.0% |
Asset Composition Trend (2014–2025)
This chart illustrates how Paradigm Biopharmaceuticals Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market value of Paradigm Biopharmaceuticals Ltd.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Paradigm Biopharmaceuticals Ltd's current assets represent 98.2% of total assets in 2025, an increase from 59.0% in 2014.
- Cash Position: Cash and equivalents constituted 68.5% of total assets in 2025, up from 3.6% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, a decrease from 41.0% in 2014.
- Asset Diversification: The largest asset category is accounts receivable at 25.9% of total assets.
Paradigm Biopharmaceuticals Ltd Competitors by Total Assets
Key competitors of Paradigm Biopharmaceuticals Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
Ascendis Pharma AS
F:A71
|
Germany | €1.30 Billion |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076
|
China | CN¥6.69 Billion |
|
Wuhan Keqian Biology Co Ltd
SHG:688526
|
China | CN¥4.75 Billion |
|
R&G PharmaStudies Co. Ltd. A
SHE:301333
|
China | CN¥2.31 Billion |
|
Shanghai Shen Lian Biomedical Corp
SHG:688098
|
China | CN¥1.56 Billion |
Paradigm Biopharmaceuticals Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 7.46 | 7.22 | 32.21 |
| Quick Ratio | 7.46 | 7.22 | 32.21 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | AU$20.89 Million | AU$20.89 Million | AU$105.01 Million |
Paradigm Biopharmaceuticals Ltd - Advanced Valuation Insights
This section examines the relationship between Paradigm Biopharmaceuticals Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 6.14 |
| Latest Market Cap to Assets Ratio | 2.12 |
| Asset Growth Rate (YoY) | -10.3% |
| Total Assets | AU$24.57 Million |
| Market Capitalization | $52.17 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Paradigm Biopharmaceuticals Ltd's assets at a significant premium (2.12x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Paradigm Biopharmaceuticals Ltd's assets decreased by 10.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Paradigm Biopharmaceuticals Ltd (2014–2025)
The table below shows the annual total assets of Paradigm Biopharmaceuticals Ltd from 2014 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | AU$24.57 Million ≈ $17.39 Million |
-10.29% |
| 2024-06-30 | AU$27.39 Million ≈ $19.38 Million |
-59.16% |
| 2023-06-30 | AU$67.07 Million ≈ $47.46 Million |
+32.32% |
| 2022-06-30 | AU$50.69 Million ≈ $35.87 Million |
-40.22% |
| 2021-06-30 | AU$84.79 Million ≈ $60.00 Million |
-24.54% |
| 2020-06-30 | AU$112.36 Million ≈ $79.50 Million |
+31.40% |
| 2019-06-30 | AU$85.51 Million ≈ $60.50 Million |
+462.90% |
| 2018-06-30 | AU$15.19 Million ≈ $10.75 Million |
+5.90% |
| 2017-06-30 | AU$14.35 Million ≈ $10.15 Million |
+16.19% |
| 2016-06-30 | AU$12.35 Million ≈ $8.74 Million |
-17.92% |
| 2015-06-30 | AU$15.04 Million ≈ $10.64 Million |
+6838.00% |
| 2014-06-30 | AU$216.80K ≈ $153.40K |
-- |
About Paradigm Biopharmaceuticals Ltd
Paradigm Biopharmaceuticals Limited engages in the research and development of therapeutic products for human use in Australia. Its lead candidate is Zilosul, an injectable pentosan polysulfate sodium drugs for the treatment of osteoarthritis, mucopolysaccharidosis, ross river virus, chikungunya virus, chronic heart failure, allergic respiratory, and acute respiratory distress syndrome diseases. … Read more